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Background: Human respiratory syncytial virus (hRSV) and human metapneumovirus (hMPV) are two of the most
frequent respiratory pathogens that circulate worldwide. Infection with either virus can lead to hospitalization of
young children, immunocompromised people and the elderly.
A better understanding of the epidemiological aspects, such as prevalence of these viruses in the population will
be of significant importance to the scientific community. The aim of this study was to gain some detailed
knowledge on the humoral immune response to both viruses in different populations of individuals.
Findings: The fusion protein (F) of hRSV and hMPV was expressed in the baculovirus and Escherichia coli systems,
respectively, and used as antigen in two independent enzyme-linked immunosorbent assays (ELISAs) for detection
of specific antibodies in human sera. The seroprevalence of each virus in a large cohort of individuals with ages
ranging from 0 to 89 years old was determined. Although the general distribution of the antibody response to
each virus in the different age group was similar, the prevalence of hRSV appeared to be higher than that of hMPV
in most of them. The group of children with ages between 0 and 2 showed the highest seronegative rates. After
this age, an increase in the antibody response was observed, most likely as the result of new infections or even due
to reinfections.
Conclusions: The use of these specific F-ELISAs in seroepidemiological studies might be helpful for a better
understanding of the human antibody response to these viruses.
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Human respiratory syncytial virus (hRSV) is the leading
cause of hospitalization for respiratory tract infections in
children [1,2]. More recently, human metapneumovirus
(hMPV), a Pneumovirus belonging also to Paramyxoviri-
dae family, has been isolated from children hospitalized
with acute respiratory infections in The Netherlands and
since, the virus has been reported worldwide [3-5].* Correspondence: psastre@ingenasa.es
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reproduction in any medium, provided the orSymptoms associated with hMPV infection are very
similar to those resulting from hRSV infection, ranging
from common cold to severe lower respiratory tract
infections, including bronchiolitis and pneumonia. No
effective vaccine is currently available towards either
hRSV or hMPV, and reinfections occur throughout life
[6-8].
The aim of this study was to analyze and compare the
specific antibody response in human serum against
hRSV and hMPV in a large cohort of individuals with
ages ranging from 0 to 89 years old. The fusion protein
(F) of both viruses appears as the most suitable candidatetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and











Figure 1 Western blot analysis of recombinant F protein of
hRSV (A) and hMPV (B). A specific pool of positive human sera
against the F protein of each virus was used to confirm the
antigenicity of the recombinant proteins. Lanes 0 represent the
molecular weight markers expressed in kDa and lanes 1 show the
reactivity against the F protein of hRSV and hMPV, respectively. The
location of the proteins is indicated with an arrow.
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antigen of the virion and highly conserved among differ-
ent strains [9-11] . For that purpose, the F protein of
hRSV and hMPV was expressed in the baculovirus and
Escherichia coli (E. coli) system, respectively, and used as
antigen in two independent ELISAs.
Materials and methods
Serum specimens
Serum samples from 1811 healthy patients were ran-
domly collected from archives of the Institute of Vir-
ology of the University Hospital Bonn.
An ethical vote from the University of Bonn Ethical
Committee permitted us to use the samples retrospect-
ively. No written informed consent was necessary as no
personal data were used and as it was an epidemiological
study. All procedures were carried out in accordance to
the Helsinki declaration in its present form.
Cloning and expression of the fusion protein of hRSV and
hMPV
A soluble version of the F protein of hRSV, Long strain
(Fs, 24-524aa) was expressed in the baculovirus system
as previously described [12].
The recombinant F protein of hMPV was prepared
using the E. coli system. The pCR4-TOPO vector con-
taining the F protein gene of hMPV (isolate NL/1/99)
was used to amplify a soluble version of the F protein
gene (Fs, nt 601–1413) by PCR with primers F + (5’-
ATGCTAAATGTTGTGCGGCAGTTT-3’) and F- (5’-
TTATCCTTTTTCTGCACTGTTTAG-3’). The PCR
product was further cloned in the pDEST™17 expression
vector (Invitrogen) that contains an N-terminal 6xHis
tag. The recombinant F protein was expressed by trans-
formation of BL21 cells. Overnight (ON) cultures of
transformed bacteria were inoculated in Luria Broth
medium supplemented with 1 % ampicillin. Cultures
were grown to exponential phase prior to induction with
arabinose 20 % for 3 hours. The F protein was partially
purified from inclusion bodies by solubilization proce-
dures using the following buffer: 50 mM Tris–HCl,
50 mM NaCl, 0.5 mM EDTA, 5 mM TCEP, 5 % glycerol
and 30 %N-Lauroylsarcosine, pH 8.
Enzyme-linked immunosorbent assay
Detection of serum antibodies against the F protein of
hRSV by ELISA has been previously published [12].
For detection of antibodies against hMPV, the recom-
binant F protein expressed in the E. coli system was used
as antigen to coat 96-well microtitre plates (0,2 μg/well).
After ON incubation at 4 °C, the wells were blocked and a
1/500 dilution of human serum in 0.05 % Tween in
Phosphate-Buffered Saline (PBS) was incubated for 1 hour
at RT. Bound antibodies were detected by incubation withperoxidase-labelled anti-human IgG and subsequent
addition of the substrate tetramethylbenzidine (TMB-
MAX, Neogen Corporation). The cut-off value of the
assay was defined by adding 2 standard deviations (SD) to
the mean optical density (OD) value of 10 negative sam-
ples [13]. These samples were previously established as
negative by comparison with negative controls tested by
immunofluorescence and kindly provided by Dr. Cathe-
rine Manoha (University Hospital Dijon).
Results
Expression of the fusion protein of hRSV and hMPV
The F protein of hRSV and hMPV were expressed using
the baculovirus and E. coli expression systems, respect-
ively. A specific pool of positive human sera against the
F protein of each virus was used to confirm the antigeni-
city of the recombinant proteins by Western blot
(Figure 1A and 1B). Incubation of the nitrocellulose
membranes with each pool of sera revealed a band cor-
responding to expected molecular mass of each recom-
binant protein.
Analysis of the antibody response towards hRSV and
hMPV
In order to investigate the incidence of hRSV and hMPV
in the population, a set of 1811 serum samples from
patients with ages ranging from 0 to 89 years of age, was
included in the present study. The specific antibody re-
sponse of each serum to the F protein of both viruses
was measured by indirect ELISA. Each serum sample
was tested at a single dilution for screening purposes.
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basis of OD yielded from the ELISA with twofold serial
dilutions of control serum samples against positive and
negative antigens prepared in the same conditions.
Figure 2 shows the seropositivity against each virus in
the different age groups. The high values of the SD in
each age group were due to a wide range of positivity
defined by the cutoff values (0.378 and 0.357 for hRSV
and hMPV, respectively). Thus, samples with OD equal
or higher than the cut-off, independently of the magni-
tude of the OD, were considered positive and sera with
readings lower than the cut-off were considered nega-
tive. The percentages of seropositive and seronegative
samples in each age group of patients are shown in
Table 1. Although the general distribution in the differ-
ent age groups for both viruses was similar, the preva-
lence of hRSV was higher than that of hMPV in the
majority of the groups.
Patients with ages between 0 and 2 years old, showed
the highest percentage of seronegative samples for the
two viruses (63.7 % for hRSV and 47.5 % for hMPV).
Then, an increase of the seropositive rates was observed
in the cohort of individuals from 2 to 9 years old, with
percentages of 71.4 % and 85.7 % for hRSV and hMPV,
respectively. The group of patients with ages between 10
and 69 years old showed an average of seropositivity of
94.8 % for hRSV and 86.6 % for hMPV. Finally, a minor
drop in the seropositivity was observed in the elderly
population between 70–89 years when measuring the
antibody response to hMPV. In the case of hRSV, the
population between 70 to 79 years old showed similar
seropositive rates to the ones of younger groups, fol-
lowed by a moderate decrease in the oldest group of
patients with ages between 80–89 years old.
Discussion
Although several studies have used single recombinant
viral proteins as ELISA antigens for measurement of
antibody response to hRSV and hMPV [14,15], this is









































Figure 2 Distribution of anti-human hRSV and hMPV antibodies
in different age groups tested by F-ELISA. Bars represent the
mean optical density of the positive serum samples included in each
age group plus the standard deviation.range of ages is tested to compare the specific antibody
response against the F protein of the two viruses. To do
so, the fusion protein of each virus was partially purified
and used in an ELISA to detect the presence of specific
antibodies in a large cohort of individuals with ages ran-
ging from 0 to 89 years. Since the F protein of each virus
was expressed in different systems and bearing in mind
that post-transductional modifications do not occur in
bacteria and the ones in insect cells differ from the ones
in mammalian cells, the antigenicity of both proteins
was first tested by Western Blot analysis with a positive
pool of human sera. A band corresponding with the
expected molecular size of each recombinant fusion pro-
tein was confirmed (Figure 1A and 1B).
By the age of 2 to 5 years most children have been
infected at least once with both hRSV and hMPV [1,4]. In
the present report, the youngest group of individuals with
ages between 0 and 2 years showed the lowest antibody
response to either virus. A broad range of ages are
included in this group with a high percentage of children
younger than 1 year old. The immaturity of the immune
system of these infants could explain the low antibody
level. Furthermore, the level of antibodies in this group
could be even lower, since some of these sera samples
may contain maternally derived antibodies, which may
not represent true seropositivity due to infection. A rise in
the antibody response against both viruses in the groups
of individuals with ages between 2–69 years old was
detected, probably as result of re-infections. Finally, the
oldest group of patients from 70 to 89 years old, showed a
significant antibody response towards both viruses, how-
ever they still comprise one of the groups at high risk of
infection with elevated rates of morbidity [16]. Previous
studies have shown that the percentage of neutralizing
antibodies against hRSV in the frail people (> 80 years
old) is very low, despite having a considerable level of spe-
cific antibodies against the virus. This poor neutralizing
antibody response is probably one of the causes for the
susceptibility of this group of individuals to develop severe
disease after infection with hRSV [17]. A recent study has
analyzed the neutralizing ability to inhibit hMPV replica-
tion using the same set of sera used in the present work
[18]. No correlation between neutralizing ability of a given
serum and antibody levels was found. Most strikingly
there was an already high neutralizing capacity of the sera
of the youngest group of patients although this group had
the highest rate of seronegativity. For the 70–79 age group
the seropositivity was 57.9 % versus 90 % neutralization.
The same was true for the other age groups in which the
presence of antibodies does not necessarily mean that
there is also a high level of neutralizing antibodies. Al-
though neutralizing ability is commonly associated with
the presence of neutralizing antibodies in a serum sample,
in the Lusebrink et al. study the authors claim that is not
Table 1 Age Seroprevalence Profiles of hRSV and hMPV









0-2 80 29 (36.25) 51 (63.75) 42 (52.50) 38 (47.50)
2-9 7 5 (71.43) 2 (28.57) 6 (85.71) 1 (14.29)
10-19 43 41 (95.35) 2 (4.65) 36 (83.72) 7 (16.28)
20-29 772 733 (94.95) 39 (5.05) 707 (91.58) 65 (8.42)
30-39 417 397 (95.20) 20 (4.80) 363 (87.05) 54 (12.95)
40-49 281 269 (95.73) 12 (4.27) 244 (86.83) 37 (13.17)
50-59 134 123 (91.79) 11 (8.21) 113 (84.33) 21 (15.67)
60-69 52 50 (96.15) 2 (3.85) 45 (86.54) 7 (13.46)
70-79 19 18 (94.74) 1 (5.26) 11 (57.89) 8 (42.11)
80-89 6 5 (83.33) 1 (16.67) 4 (66.66) 2 (33.34)
Σ 1811 (100) 1670 (92.21) 141 (7.79) 1571 (86.75) 240 (13.25)
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replication but also other neutralizing factors, such us
interferon. Taking this into consideration it is not surpris-
ing that both studies do not correlate, although the set of
sera used for both studies was identical. In concert with
the study by Lüsebrink et al. it appears likely that neutral-
izing antibodies play a minor role in the control of hMPV
and hRSV infections in humans, a hypothesis that is sup-
ported by the fact that virtually all approaches to develop
a potent and long lasting vaccine against both viruses have
failed so far.
In the present study the F protein of NL/1/99 strain
belonging to the B1 sublineage of hMPV and the F pro-
tein of the Long strain of subgroup A of hRSV have been
used. Although, as mentioned in the introduction, the
variability of the F protein belonging to the different
subgroups and sublineages of hRSV and hMPV is low, in
the developed ELISAs, some anti-F antibodies could be
disregarded and therefore false negative results could be
potentially obtained in both cases. However, it is well
known that anti-hRSV antibodies directed against the F
protein are cross-reactive for strains of both subtypes (A
and B) [19], and studies on hMPV using the F protein as
a subunit vaccine have indicated similar antibody re-
activity patterns against homologous and heterologous
hMPV infections [20,21].
Finally, as shown in Table 1, most age groups showed
that the prevalence of hRSV was higher than that of
hMPV, however children with ages from 0 to 9 years old
had higher rates of seropositivity to hMPV than to
hRSV. Several groups have studied the seroprevalence of
hMPV and hRSV in young children, with different
results. For instance, in The Netherlands all children
have been infected with hMPV by the age of 5 [4]. In
Canada, the majority of patients over 16 years old wereseropositive for hMPV [5]. In Japan, Ebihara et al found
that seropositive rates of hMPV were lower than those
of hRSV in all children between 1 month and 5 years
and a recent study in China showed that seropositive
rates of hMPV in children 6 months to 6 years of age
were significatively lower than seropositive rates of
hRSV [22,23]. This variety of results may reflect different
infection patterns between the two viruses, but also dif-
ferent seroprevalence patterns between geographical
locations.
In summary, the present study shows that the distribu-
tion of hRSV and hMPV in the general healthy popula-
tion in the area of Bonn (Germany) is very similar, with
hRSV infections more frequent that those of hMPV in
most age groups. This kind of analysis appears to be an
appropriate instrument for seroepidemiological studies,
although it should be used in combination with
neutralization test for a more comprehensive analysis.Abbreviations
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